Cancer Biopsy Market Revenues To Double By 2030, Reaching $67.22 Billion - Analysis Of Emerging Trends And Growth Strategies Shaping The Landscape

(MENAFN- GlobeNewsWire - Nasdaq) The cancer biopsy market sees opportunities in advancing minimally invasive techniques, integrating AI and imaging for improved accuracy, and optimizing workflows for enhanced efficiency. Regional adoption varies, with innovations led by major industry players.

Dublin, Sept. 03, 2025 (GLOBE NEWSWIRE) -- The "Cancer Biopsy Market by Product Type (Core Needle Biopsy, Fine Needle Aspiration, Surgical Biopsy), Application (Breast, Liver, Lung), Technology, End User - Global Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering.

The Cancer Biopsy Market has demonstrated significant growth, moving from USD 33.48 billion in 2024 to USD 37.76 billion in 2025, and is projected to reach USD 67.22 billion by 2030 with a CAGR of 12.32%. In the rapidly advancing field of oncology diagnostics, biopsy procedures serve a crucial role in personalized care. Modern technologies focus on minimally invasive methods that enhance patient outcomes while maintaining diagnostic integrity. The integration of advanced imaging modalities has augmented the accuracy and efficiency of these procedures, marking a notable evolution in clinical approaches.

Transformative Advances in Cancer Biopsy Technology

The shift from conventional invasive methods to innovative, minimally disruptive techniques marks a new era in cancer diagnosis. Technologies like vacuum-assisted systems and robotic platforms improve specimen quality and precision. Real-time analytics, enabled by machine learning, enhance procedural decision-making, reducing diagnostic times and improving outcomes. These technological advances aid healthcare providers in adopting efficient and patient-centric solutions, ensuring optimal diagnostic results in diverse clinical scenarios.

Impact of U.S. Tariffs on Cancer Biopsy Equipment

The 2025 U.S. tariffs on biopsy equipment have necessitated a reevaluation of procurement strategies. Rising import duties have pressured manufacturers, prompting strategic shifts along the supply chain, such as diversifying supplier networks and exploring local manufacturing opportunities. Healthcare facilities face potential cost increases, influencing procurement decisions and budget allocations. Collaborating with policymakers and logistics providers can mitigate these challenges, ensuring continuous access to vital diagnostic tools while maintaining market stability.

Key Takeaways from This Report

• The rapid adoption of advanced biopsy technologies is transforming diagnostic pathways and improving patient outcomes.
• U.S. tariffs pose challenges to equipment costs and supply chain dynamics, necessitating strategic adaptations across the market.
• The report provides valuable insights into the segmentation of product types, clinical applications, technological platforms, and geographic variations.
• Leaders in the industry are leveraging strategic partnerships and R&D investments to maintain competitive advantage and innovate within the oncology diagnostics sector.

These comprehensive insights aid decision-makers in developing strategies for market entry and growth, allowing them to anticipate industry shifts and capitalize on emerging opportunities.

Key Attributes

Report Attribute	Details
No. of Pages	197
Forecast Period	2025-2030
Estimated Market Value (USD) in 2025	$37.76 Billion
Forecasted Market Value (USD) by 2030	$67.22 Billion
Compound Annual Growth Rate	12.3%
Regions Covered	Global

Key Topics Covered
1. Preface
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of liquid biopsy assays for early cancer detection using ctDNA and exosomal biomarkers
5.2. Adoption of AI-driven image analysis in needle biopsy procedures to enhance diagnostic accuracy and reduce sample processing times
5.3. Development of minimally invasive robotic biopsy devices enabling precision sampling of deep-seated tumors
5.4. Expansion of next-generation sequencing panels in biopsy specimens to guide personalized oncology treatment decisions
5.5. Growth of point-of-care biopsy diagnostic platforms for rapid molecular profiling in outpatient oncology settings
5.6. Emergence of multianalyte liquid biopsy tests combining circulating tumor cells, DNA, and RNA for comprehensive tumor characterization
5.7. Regulatory approvals and reimbursement reforms driving commercialization of innovative biopsy technologies in major markets
5.8. Collaborations between diagnostic companies and academic centers to validate novel biopsy biomarkers and protocols
5.9. Rise of pan-cancer early detection assays leveraging cfDNA methylation profiling for multi-cancer screening
5.10. Integration of AI-driven decision support tools with biopsy genotyping data to predict patient outcomes and therapy response
6. Market Insights
6.1. Porter's Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025

8. Cancer Biopsy Market, by Product Type
8.1. Introduction
8.2. Core Needle Biopsy
8.3. Fine Needle Aspiration
8.4. Surgical Biopsy
8.5. Vacuum-Assisted Biopsy
9. Cancer Biopsy Market, by Application
9.1. Introduction
9.2. Breast
9.3. Liver
9.4. Lung
9.5. Prostate
9.6. Thyroid
10. Cancer Biopsy Market, by Technology
10.1. Introduction
10.2. Imaging Guided Biopsy
10.3. Manual Freehand Biopsy
10.4. Robotic Assisted Biopsy
11. Cancer Biopsy Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Diagnostic Imaging Centers
11.4. Hospitals
11.5. Physicians Offices
12. Americas Cancer Biopsy Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Cancer Biopsy Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Cancer Biopsy Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
The companies profiled in this Cancer Biopsy market report include:

• Boston Scientific Corporation
• Hologic, Inc.
• Medtronic plc
• Cardinal Health, Inc.
• Cook Medical LLC
• Becton, Dickinson and Company
• Olympus Corporation
• Argon Medical Devices, Inc.
• Teleflex Incorporated
• B. Braun Melsungen AG

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Cancer Biopsy Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN03092025004107003653ID1110010575